Online Marketing and Consultation - lead generation and management - clear and consistent messaging of client value propostion - coordinate efforts financial teams and client - monitor company and industry news - network analytics, message optimization, and team building
Private Investor with 10 years of biotech trading experience.
I use basic disciplined research approach to discover new investment ideas. Biotech sector is full of violent stock moves and trial failures. On one hand it requires traders to be quick on their feet and on the other hand it forces investors to have a great deal of patience.
I enjoy the challenge of mining for hidden gems, because its 10 times as hard to do that than predicting failures. Failure is the norm in biotech, I look for exception to the norm!
I'm Brett Sifling, and I'm the sole operator of BioStocks LLC (BioStocks.com). I'm a youngster, but work very hard to become the best I can be. I was up more than 400% in 2012 with consistent gains while detailing entries and exits on twitter (@BsiflingTrades & @BioStocksLLC). You can also view every trade I have ever made in my career here: http://profit.ly/user/bsifling
I'm an baseball player by nature, but the market has always had my interest. It is my calling, and I enjoy every minute of it. I continue to blog, trade, and share thoughts on a 24/7 basis while helping others with what I've learned along the way on my subscription website.
With a focus on out-of-favor equities in the volatile high-technology, biotechnology, and natural resources sectors, we invest in companies with hidden deep value. The fund is led by a veteran researcher, whose core competency is in unraveling murky stories and strategically sifting through fundamentals.
With our experience, we hope to help readers discover alpha in areas most investors are not - or refuse to be - looking.
I am a long and short term trader that has been involved with the stock market for many years. Primarily a technical analyst to trade, I enjoy diving into the microcap stock world looking for hidden gems. I am looking for companies that meet a select criteria of strong management, products either already on the market or possibly "in the pipeline" for biotechs. I never completely finish my due diligence when I discover a company that I like as I will maintain constant contact with a member of upper level management on a regular basis.
OTC Showcase is in the business of providing corporate information to create market and public awareness for publicly traded companies and do so through our website and affiliates. In some cases, OTC Showcase has been compensated to provide the information to the public. In some cases, the information is provided to us and we do all that we can to ensure the accuracy of the information, but cannot guarantee all information to be accurate. Information in our emails, press releases, message board postings and on our Web site may contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934 and must be realized as such. We are not licensed financial advisors in any way, shape or form and none of the information provided should be used as investment advice. Always consult a qualified and licensed financial advisor before making any investment as investing and trading can contain high elements of risk in which you may lose some or all of your money. OTC Showcase always intends to remain 100% compliant with Section 17(b) of the Security Act of 1933 and fully disclose any compensation. Please view our full disclaimer/disclosure at http://www.otcshowcase.com/?page_id=190.
China has become the #2 pharmaceutical market years ahead of projections and continues to be the fastest growing market in the world. China is $50 billion dollars a year into life science and healthcare development through over 160 government funding programs. VC investment, M&A transactions and cross-border partnering deals in China were all up significantly in 2012.
ChinaBio® Today focuses exclusively on the rapidly evolving life science industry in China, including biotech, pharma, medical device, diagnostics, services and tools. From our offices in Shanghai and San Diego, our industry analysts provide daily news, commentary and analysis on public and private China life science companies, as well as events and global issues affecting the China market.
Visit: ChinaBio Today (http://www.chinabiotoday.com)
ChinaBio LLC (http://www.chinabiollc.com)
I’m CEO of San Diego Biotechnology Connection (https://sandiegobiotechnology.com). I have a M.S. degree (microbiology) from the University of Iowa and completed a one-year science journalism fellowship at MIT. I have been an award-winning science writer and editor for 30 years for newspapers, magazines and research institutes and I have won numerous awards from state medical societies, state Associated Press Managing Editors associations, the American College of Emergency Physicians and a Silver Gavel Award from the American Bar Association. I was senior director of communications for UC San Diego prior to founding San Diego Biotechnology Connection.
My name is Troy and I am a journalist that follows the stock market and occasionally invests on value stocks, those that I consider well below the company's "sticker-price." I have a Master's in Business Administration from Florida Institute of Technology (FIT). I work as a Cost Analyst for the Department of Defense, essentially costing out multi-million dollar projects and determining Return on Investment
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to building shareholder value.
View our website at www.MissionIR.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit http://disclaimer.missionir.com.
Spent my entire 28 year career on Wall Street with over a decade at Bear Stearns. No "Wall Street Titan" in real life but WST is an alias that I've used for years on Yahoo so I use it when I write on SA. I have gained a significant amount of knowledge regarding the stem cell sector over the years and have recently launched a premium service covering this exciting area.
I am a fundamentals-driven individual investor with a passion for in-depth analysis of the securities that I consider for my portfolio. Although my focus is typically on top-level analysis (market > sector > industry > competitive groups > stock), I occasionally diverge when a special scenario warrants my attention. I appreciate when others provide a full background of all relevant issues affecting an investment decision, and I hate when others overlook pertinent facts, purposefully or not. I consider my money my family's and do not take investment decisions lightly. I appreciate the opportunity to contribute to the great community that Seeking Alpha has become and welcome any comments about my work.
GuruFundPicks.com offers top buy & sell picks based on the collective or Consensus Picks' of over 330 of our hand-picked top hedge & mutual fund managers, incl. 78 legendary or guru fund managers, 27 of the world's largest or mega funds, 165 sector-focused funds (in gold, biotech, tech, energy, consumer, finance & REITs), 59 billionaires, 54 new masters and 40 tiger, 52 shareholder activist and our Winners Circle Top 100 Performing Hedge Fund Managers (updated quarterly). We offer market-beating tools and services including Consensus Picks' DIY Tools, Top 20 Small-Cap and Top 30 All-Cap Long/Short Newsletters based on the Consensus Picks system, and Trade Alert Services for Self & Auto-Trading. All of our services have beaten market averages by wide margins. See our website GuruFundPicks.com for the latest performance numbers, or contact us at support@GuruFundPicks.com.
The two authors are co-managers of a family partnership long/short equity fund since 2001, that have a successful track record in trading primarily small-cap aggressive growth companies based on a fundamental valuation analysis of current news, including quarter reports, guidance, biotech clinical study results and other news. The junior partner is a self-taught private investor with a Business degree from the New York University's Leonard N. Stern School of Business and the senior partner has an MBA from the University of Virginia Darden School of Business, including prior MS & BS (Engg.) degrees, and with experience in business strategy consulting to large fortune 100 companies.
We are generally sector and market-cap agnostic, identifying opportunities using a 'stock picking' bottom-up, fundamentals-based, valuation-driven approach. However, we find most opportunities in the small-cap space, in technology & healthcare sectors, with some also found often in the consumer, energy & basic materials sectors.
Follow us on Seeking Alpha and Twitter (@GuruFundPicks), and connect with us on LinkedIn (http://www.linkedin.com/in/manishbabla)
Full Time Micro Cap Investor. Founder of MicroCapClub.com
Founded in 2011, MicroCapClub is an exclusive forum for experienced microcap investors focused on microcap companies (sub $300m market cap). MicroCapClub was created to be a platform for experienced microcap investors to share and discuss stock ideas. MicroCapClub’s mission is to foster the highest quality microcap investor Community, produce Educational content for investors, and promote better Leadership in the microcap arena.
I am a global macro investor, financial journalist and weekend entrepreneur. As a global macro investor, I like to make bets on countries/regions using ETFs/options and usually have a six month to one year timeframe. As a financial journalist, I write for About.com's International Investing section, Investopedia.com, and a number of other places. And as a weekend entrepreneur, I enjoy developing website and mobile apps to learn new languages/technologies.
Alexander Shadunsky began his career in business at a young age, when he became a part of the family newspaper business. After a brief stint in retail, he developed an interest in value investing and has been uncovering undervalued opportunities ever since. He is a regular reader of Seeking Alpha, Value Investor’s Club, and SEC documents.
Currently, Mr. Shadunsky is a small business consultant. He has spent time working on a wide variety of projects including business and equity valuations, corporate finance, business process automation, corporate communications, and strategic branding and positioning.
Mr. Shadunsky earned a bachelor’s degree in Finance from the Rochester Institute of Technology and has studied business at Indiana University as well. Previously, Mr. Shadunsky worked as an equity analyst at Briefing.com where he covered biotechnology and pharmaceutical stocks. He also spent time with Xerox and Merrill Lynch. He is fluent in Russian.
He can be contacted at alexs85(at)gmail.com.
I am a small-time writer/blogger who dreams big and enjoys researching and writing about biotechs and pharmaceuticals. My work experiences include food safety, water quality, pesticides, food additives, paints, plastics and pharmaceutical precursors. My focus as of late has been researching the treatment options for many cancers and prevention of their recurrence. Additional recent research has been in the stem cell field, an exciting field in its infancy but now becoming a teenager! My ongoing goal for investors is attempting to find under-the-radar or oversold pharmaceuticals or biotechs for investment potential.
Dr. John L. Faessel is a seasoned and respected Wall Street professional with industry-wide recognition for expertise in market strategy and analysis. He is widely recognized for his insights in public companies. For over 20-years Dr. Faessel’s ON THE MARKET reports have been widely distributed to a throughout the world to an extensive list of financial institutions, investment banking firms, brokers, foundations, mutual funds, hedge funds and private high net worth investors. Dr. Faessel is also a daily contributor to the widely read JagNotes.com, Wall Streets oldest daily rag.
John Eastman is a writer, mixed media artist, and founder of several businesses (www.redfishcreative.com) (www.eastmantribe.com)with over 25 years of hands-on business and entrepreneurial experience. He currently works and resides in a studio loft in Pittsburgh, Pennsylvania and NYC. Mr. Eastman has exhibited and read in various galleries and exhibits in the region as an artist and writer.
Mr. Eastman is the co-founder of www.smallcapcity.com, an online publication that focuses on small capitalized public firms, founder of www.blackandwhiteprogram.com, an online publication offering interviews, essays, and reports. He also writes for www.thechairmansblog.com, www.smallcapcity.com, Motley Fool, and several other online and print publications.
Mr. Eastman’s business background commenced in 1985 with the launch of a series of high tech, real estate, and design firms. He has extensive experience in banking and loan servicing, real estate property management and asset management, asset appraisal and valuation, Office of Thrift Supervision (OTS) and FDIC bank closure proceedings.